无创双水平正压通气与呼吸兴奋剂辅助治疗慢阻肺急性呼吸衰竭的疗效

Noninvasive bi-level positive pressure ventilation and respiratory stimulant assisted therapy for acute respiratory failure of chronic obstructive pulmonary disease

目的探索无创双水平正压通气联合呼吸兴奋剂治疗慢阻肺急性呼吸衰竭的效果。方法在本院呼吸内科2017年3月至2018年5月收治的慢阻肺急性呼吸衰竭患者中选出160例为对象,根据治疗方法分组:对照组给予常规对症支持治疗和呼吸兴奋剂治疗,观察组在对照组的基础上给予无创双水平正压通气,对比两组患者的治疗总有效率等。结果观察组治疗总有效率明显高于对照组治疗总有效率(P<0.05);治疗24h、72h的动脉血气指标对比:观察组的PaCO2明显低于对照组(P<0.05);观察组的PaO2明显高于对照组(P<0.05);两组的pH值对比差异无统计学意义;观察组的住院时间短于对照组(P<0.05);不良反应发生率对比:观察组5.0%,对照组6.25%,两组患者差异无统计学意义。结论无创双水平正压通气联合呼吸兴奋剂治疗慢阻肺急性呼吸衰竭疗效确切,促进患者通气状况改善,提高治疗效果。

Objective To explore the effect of non-invasive bi-level positive pressure ventilation combined with respiratory stimulants in the treatment of chronic obstructive pulmonary disease (COPD) with acute respiratory failure. Methods 160 cases of COPD patients with acute respiratory failure were selected from the respiratory department of our hospital from March 2017 to May 2018. According to the treatment methods, the control group was given routine symptomatic support treatment and respiratory stimulant treatment, while the observation group was given non-invasive bi-level positive pressure ventilation on the basis of the control group, and the total effective rate of treatment was compared between the two groups. Results The total effective rate of the observation group was significantly higher than that of the control group (P<0.05);the arterial blood gas index of the observation group was significantly lower than that of the control group (P<0.05);the PaCO2 of the observation group was significantly higher than that of the control group (P<0.05);the pH value of the two groups had no significant difference;the hospitalization time of the observation group was shorter than that of the control group (P<0.05);The incidence of adverse reactions was 5.0% in the observation group and 6.25% in the control group. There was no significant difference between the two groups. Conclusion Non-invasive bi-level positive pressure ventilation combined with respiratory stimulants is effective in the treatment of COPD with acute respiratory failure, which can improve the ventilation status and improve the therapeutic effect.